Early-stage hepatocellular carcinoma (HCC) is typically clinically silent, and HCC is often
advanced at first manifestation. Without treatment, the 5-year survival rate is less than 5 …

Improvements in diagnostic techniques have enhanced our understanding of the natural
history of hepatocellular carcinoma (HCC). This has facilitated a proper evaluation of the …

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third
cause of cancer-related death. Despite therapeutic advances, the overall survival of patients …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Despite
efforts for prevention and screening as well as development of new technologies for …

Hepatocellular carcinoma is the third most frequent cause of death from cancer and the
eighth most commonly occurring cancer in the world. In the United States, hepatocellular …

Hepatocellular carcinoma is the most frequent primary malignancy of the liver and appears
to be rising in incidence in the United States and other developed westerm countries …

Hepatocellular carcinoma (HCC) typically occurs in patients with advanced liver disease, so
therapeutic decisions must account for the degree of underlying liver dysfunction and patient …

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with
an estimated 350,000 new cases per year. 49 The most important predisposing factors are …

Hepatocellular carcinoma (HCC) is frequently diagnosed at advanced stages and has a
high mortality rate. With improved survival of patients with cirrhotic liver disease and …

The incidence of hepatocellular carcinoma continues to increase worldwide. Fortunately,
there have been notable recent advances in locoregional and systemic therapy. In this …